1. Cancer. (2021). Retrieved 24 August 2021, from https://www.who.int/news-room/fact-sheets/detail/cancer
2. Riset Kesehatan Dasar (Riskesdas) (2018). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI tahun 2018. http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_20 18/Hasil%20Riskesdas%202018.pdf
3. Song Y, Zhong X, Gao P, et al. Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review. Front Endocrinol (Lausanne). 2020 Jan 23;11:3. doi: 10.3389/fendo.2020.00003.
4. U.S. Preventive Services Task Force (2007). Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine, 146(5), 361–364.
5. Dehmer SP, Maciosek MV, Flottemesch TJ, et al. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21;164(12):777-86. doi: 10.7326/M15-2129.
6. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016 Mar;16(3):173-86. doi: 10.1038/nrc.2016.4.
7. Ornelas A, Zacharias-Millward N, Menter DG, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 Jun;36(2):289-303. doi: 10.1007/s10555-017-9675-z. PMID: 28762014; PMCID: PMC5557878.
8. Zumwalt TJ, Wodarz D, Komarova NL, et al. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. Cancer Prev Res (Phila). 2017 Mar;10(3):208-218. doi: 10.1158/1940-6207.CAPR-16-0175. Epub 2017 Feb 2. PMID: 28154202; PMCID: PMC5337164.
9. Zhang Y, Lv C, Dong Y, Yang Q. Aspirin-targeted PD-L1 in lung cancer growth inhibition. Thorac Cancer. 2020 Jun;11(6):1587-1593. doi: 10.1111/1759-7714.13433.
10. Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med. 2018 Jan 2;215(1):115-140. doi: 10.1084/jem.20170681. Epub 2017 Nov 30. PMID: 29191914; PMCID: PMC5748851.
11. Gilligan MM, Gartung A, Sulciner ML, et al. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6292-6297. doi: 10.1073/pnas.1804000116. Epub 2019 Mar 12. PMID: 30862734; PMCID: PMC6442621.
12. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479. PMID: 24899309; PMCID: PMC4263681.
13. Nan H, Hutter CM, Lin Y, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015 Mar 17;313(11):1133-42. doi: 10.1001/jama.2015.1815. PMID: 25781442; PMCID: PMC4382867.
14. Friis S, Riis AH, Erichsen R, et al. Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Ann Intern Med. 2015 Sep 1;163(5):347-55. doi: 10.7326/M15-0039. PMID: 26302241.
15. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50. doi: 10.1016/S0140-6736(10)61543-7. Epub 2010 Oct 21. PMID: 20970847.
16. Simon TG, Duberg AS, Aleman S, et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med. 2020 Mar 12;382(11):1018-1028. doi: 10.1056/NEJMoa1912035. PMID: 32160663; PMCID: PMC7317648.
17. Cao Y, Nishihara R, Wu K, et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol. 2016 Jun 1;2(6):762-9. doi: 10.1001/jamaoncol.2015.6396. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579. PMID: 26940135; PMCID: PMC4900902.
18. García Rodríguez, L. A., Martín-Pérez, M., Hennekens, C. H., Rothwell, P. M., & Lanas, A. (2016). Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PloS one, 11(8), e0160046. https://doi.org/10.1371/journal.pone.0160046
19. McNeil JJ, Nelson MR, Woods RL, et al; ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1519-1528. doi: 10.1056/NEJMoa1803955.
20. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5. PMID: 25096604; PMCID: PMC4269341.
21. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011;124(5):426-433. doi:10.1016/j.amjmed.2010.12.022